(Q57470658)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

title

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Luigi Formisano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Lisa N Kinch

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Paula González Ericsson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Dhivya R Sudhan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Eric H Bernicker

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Richard Lanman

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

author name string

Rebecca J Nagy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Aju Mathew

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Massimo Cristofanilli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Jie He

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Richard E Cutler

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Alshad S Lalani

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Vincent A Miller

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Carlos L Arteaga

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Nick V Grishin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

language of work or name

English

0 references

publication date

12 October 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

page(s)

277-289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

28 April 2020

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6320312/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

12 December 2020

Gapped BLAST and PSI-BLAST: a new generation of protein database search programs

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor

1 reference

12 December 2020

Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

1 reference

12 December 2020

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

1 reference

12 December 2020

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

12 December 2020

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

1 reference

12 December 2020

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

12 December 2020

HER-2 gene amplification can be acquired as breast cancer progresses

1 reference

12 December 2020

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

12 December 2020

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

1 reference

12 December 2020

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy

1 reference

12 December 2020

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

1 reference

12 December 2020

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

1 reference

12 December 2020

RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation

1 reference

12 December 2020

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

1 reference

12 December 2020

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

12 December 2020

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

1 reference

12 December 2020

On the relation between residue flexibility and local solvent accessibility in proteins.

1 reference

12 December 2020

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

12 December 2020

Mechanisms of Endocrine Resistance in Breast Cancer

1 reference

12 December 2020

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

1 reference

12 December 2020

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

1 reference

12 December 2020

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

1 reference

12 December 2020

SDM--a server for predicting effects of mutations on protein stability and malfunction

1 reference

12 December 2020

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

1 reference

12 December 2020

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

1 reference

12 December 2020

The ERBB network: at last, cancer therapy meets systems biology.

1 reference

12 December 2020

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

1 reference

12 December 2020

Activating HER2 mutations in HER2 gene amplification negative breast cancer

1 reference

12 December 2020

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

1 reference

12 December 2020

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

1 reference

12 December 2020

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics

1 reference

12 December 2020

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations

1 reference

12 December 2020

ECOD: an evolutionary classification of protein domains.

1 reference

12 December 2020

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

1 reference

12 December 2020

HER2 missense mutations have distinct effects on oncogenic signaling and migration.

1 reference

12 December 2020

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

1 reference

12 December 2020

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer

1 reference

12 December 2020

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

1 reference

12 December 2020

Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer.

1 reference

12 December 2020

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

1 reference

12 December 2020

10.1158/1078-0432.CCR-18-1544

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30314968%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

PubMed publication ID

30314968

1 reference